PAX5 and acute lymphoblastic leukemia: For instance, increasing the expression of SMN2 may have clinical utility in patients with spinal muscle atrophy owing to SMN1 mutations (66–71), and increased expression of PAX2 or PAX8 may be of interest in patients with predisposition to acute lymphoblastic leukemia due to PAX5 mutations (72).